Related Experiment Videos
[Chemotherapy of malignant brain tumors--scientific basis for combination chemotherapy]
1Dept. of Neurosurgery, Osaka University Medical School.
Abstract:
In the past decade, many clinical trials have been explored for the search of effective chemotherapy against malignant gliomas. However, to date, no significant prolongation of the survival in adults malignant gliomas have been demonstrated by these approaches. Chemotherapy currently adds little to radiotherapy in these patients. In solid tumors responsive to chemotherapy, multiple effective agents are combined. The design of a chemotherapy regimen using multiple drugs should be planned on the basis of several scientific theories concerning with tumor biology. Among them, concepts of the alternating noncross resistance chemotherapy (Goldie-Coldman) and dose-intense chemotherapy were described in relation to application to the chemotherapy of gliomas.
Insights
Despite extensive research, chemotherapy offers limited survival benefits for adult malignant gliomas. Novel combination and dose-intense chemotherapy strategies, based on tumor biology, are needed to improve treatment efficacy.
Area of Science:
- Neuro-oncology
- Clinical pharmacology
- Cancer biology
Context:
- Malignant gliomas remain challenging to treat, with limited survival improvements from current chemotherapy.
- Chemotherapy provides minimal added benefit to radiotherapy in adult malignant gliomas.
- Solid tumors often respond better to combination chemotherapy regimens.
Purpose:
- To explore novel chemotherapy strategies for malignant gliomas.
- To investigate the application of tumor biology principles in designing glioma chemotherapy.
- To evaluate the potential of alternating non-cross resistance and dose-intense chemotherapy.
Summary:
- Clinical trials over the past decade have not significantly improved survival for adult malignant gliomas.
- Current chemotherapy regimens offer little advantage when combined with radiotherapy.
- The study discusses applying tumor biology theories, including the Goldie-Coldman alternating non-cross resistance and dose-intense chemotherapy concepts, to glioma treatment.
Impact:
- Highlights the need for innovative chemotherapy approaches in neuro-oncology.
- Suggests a shift towards biologically-guided combination and dose-intense chemotherapy for gliomas.
- Aims to inform future clinical trial designs for more effective malignant glioma treatment.